Awareness and Knowledge among Internal Medicine House-staff for Dose adjustment of Commonly Used Medications in Patients with CKD by Surana, Sikander et al.
City University of New York (CUNY) 
CUNY Academic Works 
Publications and Research Brooklyn College 
2017 
Awareness and Knowledge among Internal Medicine House-staff 
for Dose adjustment of Commonly Used Medications in Patients 
with CKD 
Sikander Surana 
Nassau University Medical Center 
Neeru Kumar 
Nassau University Medical Center 
Amita Vasudeva 
Nassau University Medical Center 
Gulvahid Shaikh 
Nassau University Medical Center 
Kenar D. Jhaveri 
North Shore University Hospital 
See next page for additional authors 
How does access to this work benefit you? Let us know! 
More information about this work at: https://academicworks.cuny.edu/bc_pubs/135 
Discover additional works at: https://academicworks.cuny.edu 
This work is made publicly available by the City University of New York (CUNY). 
Contact: AcademicWorks@cuny.edu 
Authors 
Sikander Surana, Neeru Kumar, Amita Vasudeva, Gulvahid Shaikh, Kenar D. Jhaveri, Hitesh Shah, Deepa 
Malieckal, Joshua Fogel, Gurwinder Sidhu, and Sofia Rubinstein 
This article is available at CUNY Academic Works: https://academicworks.cuny.edu/bc_pubs/135 
RESEARCH ARTICLE Open Access
Awareness and knowledge among internal
medicine house-staff for dose adjustment
of commonly used medications in patients
with CKD
Sikander Surana1, Neeru Kumar1, Amita Vasudeva1, Gulvahid Shaikh1, Kenar D. Jhaveri2, Hitesh Shah2,
Deepa Malieckal2, Joshua Fogel3, Gurwinder Sidhu1 and Sofia Rubinstein1*
Abstract
Background: Drug dosing errors result in adverse patient outcomes and are more common in patients with
chronic kidney disease (CKD). As internists treat the majority of patients with CKD, we study if Internal Medicine
house-staff have awareness and knowledge about the correct dosage of commonly used medications for those
with CKD.
Methods: A cross-sectional survey was performed and included 341 participants. The outcomes were the
awareness of whether a medication needs dose adjustment in patients with CKD and whether there was
knowledge for the level of glomerular filtration rate (GFR) a medication needs to be adjusted.
Results: The overall pattern for all post-graduate year (PGY) groups in all medication classes was a lack of awareness
and knowledge. For awareness, there were statistically significant increased mean differences for PGY2 and PGY3 as
compared to PGY1 for allergy, endocrine, gastrointestinal, and rheumatologic medication classes but not for analgesic,
cardiovascular, and neuropsychotropic medication classes. For knowledge, there were statistically significant increased
mean differences for PGY2 and PGY3 as compared to PGY1 for allergy, cardiovascular, endocrine, and gastrointestinal,
medication classes but not for analgesic, neuropsychotropic, and rheumatologic medication classes.
Conclusions: Internal Medicine house-staff across all levels of training demonstrated poor awareness and knowledge
for many medication classes in CKD patients. Internal Medicine house-staff should receive more nephrology exposure
and formal didactic educational training during residency to better manage complex treatment regimens and prevent
medication dosing errors.
Keywords: Chronic kidney disease, Medication dose adjustment, Dosing errors, Internal medicine, Internship and
residency
Background
Chronic kidney disease (CKD) is an important health
problem with a rising incidence and prevalence in the
general United States (US) population [1, 2]. Over the
past two decades, there has been a 10–20% increase in
incidence and prevalence of CKD stages 3–5 [3, 4]. CKD
prevalence in the US general population is 13.6% [5].
This prevalence is even higher in patients with pre-
diabetes (18%), diabetes (40–42%) and the elderly (23–
58%) [6–10]. The elderly are a growing population with
demographic models projecting their number to increase
to about 1 in 5 people by the year 2030 [11].
The steep increase in the prevalence of CKD among
the elderly might be partly due to related co-morbidities
such as cardiovascular diseases, diabetes or hypertension
[12]. Further, patients with CKD are at increased risk for
cardiovascular and non-cardiovascular diseases, includ-
ing infection and malignancy [13, 14]. With the increase
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in these co-morbid conditions with increasing age,
elderly patients receive a large number of medications
[15, 16]. These multiple drugs and complex regimens to
achieve treatment goals for management of both CKD
complications and various co-morbidities, put the elderly
at a higher risk for drug related problems [15, 17].
Polypharmacy is highly prevalent and dosing error is
one of the most important drug related problems in the
elderly [18–23]. In a study of elderly patients in the US,
over half reported the combined use of 5 or more
prescription/non-prescription medications or dietary
supplements [24]. In a similar study of elderly patients
from Austria, the mean number of drugs taken was 7.5
with 58.4% of the elderly patients fulfilling their criteria
for polypharmacy of more than 6 drugs [25]. Polyphar-
macy appears to be amplified in patients with CKD with
one study reporting a mean of 8 medications in elderly
patients with CKD stages 3 through 5 [26].
Many medications require dose adjustment in patients
with CKD. Incorrect drug dosing was reported in 23.4%
of patients, the majority of whom had renal impairment
[25]. A review that assessed clinicians’ adherence to dos-
ing guidelines for CKD patients reported nonadherence
rates ranging from 19 to 67% [19]. A recent study fur-
ther highlights this problem and reports that of the total
1464 antibiotic prescriptions filled for patients with
CKD, 970 (66.3%) were for doses in excess of recom-
mended guidelines [27]. Drug dosing errors can result in
adverse effects, poor patient outcomes, and contribute
to excess financial expenditures [28]. Adverse drug
events are one of the top 7 leading causes of death in US
and Canada [28–31]. In the US, annually more than
200,000 people die and another 2.2 million people are
injured because of medication related problems [29, 32].
The cost associated with medication-related problems is
estimated at over $2 billion per year in the US [33].
Due to a growing CKD population coupled with the
often limited number of nephrologists and late referrals,
the majority of CKD patients receive their ambulatory
care from primary care physicians [16, 34]. In addition, pa-
tients with CKD are at increased risk for hospitalization
where they are cared for by generalists [3, 35, 36]. It is im-
portant to determine if Internal Medicine (IM) house-staff
are obtaining the knowledge necessary to correctly dose
medications in a CKD population. To the best of our
knowledge this has not been studied worldwide. We study
awareness and knowledge among IM house-staff of dosage
adjustment for commonly used medications across differ-
ent medication classes in patients with CKD.
Methods
Participants and setting
We conducted a cross sectional survey to assess aware-
ness and knowledge among 341 IM house-staff for
dosage adjustment of commonly used medications
across different medication classes in patients with CKD.
The study was performed at six academic hospitals
located in New York City and its suburbs. IM house-
staff across all levels of training were surveyed in their
fourth through sixth month of their training year.
Variables
The following demographic information was collected:
age (years), sex, medical school (graduate of American
or International medical school), and level of training
(post-graduate year (PGY)1, PGY2, PGY3 or greater).
Personal/family history of kidney disease (personal his-
tory and/or history of kidney problems among spouse or
children, and presence or absence of kidney problems in
any first-degree relatives) was obtained. A renal training
score (ranging from 0 to 3 for each affirmative response)
consisted of the following: prior nephrology training or
renal electives in medical school or residency, regular at-
tendance at renal clinic (defined as 10 times or more
during training), and interest in nephrology for further
training.
A list of 26 commonly used medications was compiled
representing 7 different medication classes: allergy (di-
phenhydramine, loratadine, montelukast), analgesic
(acetaminophen, ibuprofen, meperedine, tramadol), car-
diovascular (amlodipine, atenolol, carvedilol, digoxin,
enalapril, hydralazine, simvastatin), endocrine (glipizide,
pioglitazone, sitagliptin), gastrointestinal (famotidine,
pantoprazole), neuropsychotropic (alprazolam, gabapen-
tin, haloperidol, levetiracetam, paroxetine), and rheuma-
tologic (allopurinol, colchicine). We offered the
following possible responses to each medication: a) does
not need dose adjustment, b) needs dose adjustment at
glomerular filtration rate (GFR)<90 ml/min, c) needs
dose adjustment at GFR<60 ml/min, d) needs dose
adjustment at GFR<30 ml/min, and e) I don’t know.
Outcome variables
One outcome was to assess the awareness among
house-staff whether a given medication needed dose
adjustment in patients with impaired renal function
(‘medication dose needs adjustment’ awareness). The
other outcome was to assess the knowledge among
house-staff whether they knew at what level of GFR a
given medication needs to be adjusted (‘medication
dose adjustment at appropriate GFR level’ knowledge)
according to published medication dosing guidelines in
CKD [37, 38]. A score of ‘one’ was assigned for every
correct response to a medication. A total score was
calculated for each medication class and also for all
medications (’overall medication score’).
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Statistical analyses
Descriptive statistics of either mean and standard devi-
ation or frequency and percentage were used to describe
the variables. The independent variable was post-
graduate year (PGY). One outcome was correct ‘medica-
tion dose needs adjustment’ awareness and the other
was correct ‘medication dose adjustment at appropriate
GFR level’ knowledge. Analysis of variance (ANOVA)
was conducted for total of all medications and also seven
different medication classes. For the analyses with statis-
tically significant differences, least significant difference
(LSD) post-hoc analyses and analysis of covariance
(ANCOVA) were conducted. The covariates included in
the ANCOVA analyses were age, sex, medical school
location, personal/family history of kidney disease, and
renal training score. For the outcome variable with a
skewed distribution, non-parametric analyses of the
Kruskal Wallis test instead of ANOVA, Mann–Whitney
tests instead of LSD post-hoc tests, and rank ANCOVA
(Quade’s test) instead of ANCOVA were performed. A
total score of all medications was calculated for all the
341 participants counting only the correct responses.
Also, to allow for including the greatest number of
participants in the ANCOVA analyses, the 34 individuals
who omitted age were imputed with the mean sample
age. SPSS Version 22 was used for all analyses. All p-
values were two-sided.
Results
Table 1 shows the descriptive statistics of the sample.
Mean age was almost 30 years. Men were slightly more
than women. Approximately equal numbers received
their medical school training in the US and internation-
ally. Almost half surveyed comprised of PGY1, with the
PGY2 and PGY3 comprising approximately one-quarter
for each group. Slightly more than one-tenth had a
personal/family history of kidney disease. Mean renal
training score was below 1 on a scale with a total pos-
sible score of 3.
Table 2 shows comparisons for PGY groups for total
scores for correct ‘medication dose needs adjustment’
awareness for different medication classes in CKD.
ANOVA showed statistically significant mean differences
for the PGY groups for total score of all medications,
and also allergy, endocrine, gastrointestinal, and rheu-
matologic medication classes. These results were main-
tained in ANCOVA analyses adjusting for the relevant
covariates. LSD post-hoc analyses showed that PGY2
had significantly greater mean scores than PGY1 for
total score of all medications (p = 0.01), and also for
allergy (p = 0.03), endocrine (p = 0.001), gastrointestinal
(p = 0.004) and rheumatologic (p < 0.001) medication
classes. LSD post-hoc analyses showed that PGY3 had
significantly greater mean scores than PGY1for total
score of all medications (p < 0.001), and also allergy (p =
0.001), endocrine (p < 0.001), gastrointestinal (p < 0.001),
and rheumatologic (p < 0.001) medication classes. Also,
LSD post-hoc analyses for endocrine showed that PGY3
had significantly greater mean scores than PGY2 (p =
0.01). There were no statistically significant mean differ-
ences for PGY groups for analgesic, cardiovascular, and
neuropsychotropic medication classes. As can be seen by
the mean scores, there was an overall pattern for all
PGY groups in all medication classes except for rheuma-
tologic where there was lack of correct knowledge. For
rheumatologic medication class, PGY3 had 90.0% ‘com-
pletely correct’ (correct response for all the medications
in a given class), PGY2 had 76.8% ‘completely correct’,
and PGY1 had 55.3% ‘completely correct’ responses. An
analysis of the 6 remaining medication classes showed
that the highest percentage of ‘completely correct’ re-
sponse for any particular medication class for any of the
PGY groups was 17.1% for gastrointestinal (Fig. 1). For
total score of all medications, no one scored 26/26
correct. Those who scored 20 or greater correct were 1
participant who scored 20/26 (0.3%) correct and 2 par-
ticipants who scored 25/26 correct (0.6%).
Table 3 shows comparisons for PGY groups for total
scores for correct ‘medication dose adjustment at appro-
priate GFR level’ knowledge for different medication
classes in CKD. ANOVA analyses showed statistically
significant mean differences for the PGY groups for total
score of all medications, and also allergy, cardiovascular,
and gastrointestinal medication classes. The Kruskal
Wallis test showed statistically significant mean
Table 1 Descriptive Statistics of a Sample of 341 Internal
Medicine Residents
Variables Frequency Percent Mean SD












PGY3 and greater 82 24.0
Kidney disease history (yes) 36 10.6
Renal training score 0.7 0.76
Note: PGY post-graduate year, SD standard deviation
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differences for endocrine medication class. These results
were maintained in ANCOVA analyses after adjusting
for the relevant covariates. LSD post-hoc analyses (or
Mann Whitney tests for endocrine) showed that PGY2
had significantly greater mean scores than PGY1 for
total score of all medications (p < 0.001), and also for
allergy (p = 0.001), cardiovascular (p = 0.01), endocrine
(p = 0.02), and gastrointestinal (p = 0.003) medication
classes. LSD post-hoc analyses showed that PGY3 had
significantly greater mean scores than PGY1 for total
score of all medications (p < 0.001), and also for allergy
(p < 0.001), cardiovascular (p = 0.004), endocrine (p <
0.001), and gastrointestinal (p = 0.001) medication
classes. There were no statistically significant mean
differences for PGY groups for analgesic and neuropsy-
chotropic medication classes, while rheumatologic medi-
cation class approached statistical significance for an
overall statistical difference between the PGY groups. As
can be seen by the mean scores, there was an overall
pattern for all PGY groups in all medication classes
where there was lack of correct knowledge. An analysis
of the 7 different medication classes showed that the
highest percentage of ‘completely correct’ response for
any particular medication class for any of the PGY
groups was 16.3% for rheumatologic medications (Fig. 2).
For total score of all medications, no one scored 26/26














Allergy 3 1.3 (0.85) 1.6 (0.71) 1.7 (0.59) 0.003 0.046 PGY2>PGY1
PGY3>PGY1
Analgesic 4 1.3 (1.03) 1.1 (0.90) 1.4 (0.91) 0.19 – –
Cardiovascular 7 3.4 (1.36) 3.6 (1.09) 3.6 (0.93) 0.27 – –
Endocrine 3 1.1 (0.86) 1.5 (0.76) 1.8 (0.67) <0.001 <0.001 PGY2>PGY1
PGY3>PGY1
PGY3>PGY2
Gastrointestinal 2 0.8 (0.56) 1.0 (0.52) 1.0 (0.54) <0.001 0.001 PGY2>PGY1
PGY3>PGY1
Neuropsychotropic 5 2.1 (1.28) 2.2 (1.00) 2.2 (0.97) 0.79 – –
Rheumatologic 2 1.4 (0.78) 1.7 (0.55) 1.9 (0.48) <0.001 <0.001 PGY2>PGY1
PGY3>PGY1
Overall medication score 26 11.2 (4.31) 12.4 (3.28) 13.3 (2.10) <0.001 0.002 PGY2>PGY1
PGY3>PGY1




























































Fig. 1 ‘Medication dose needs adjustment’ awareness. Percent ‘completely correct’ responses by PGY groups
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correct. Those who scored 20 or greater correct were 1
participant who scored 21/26 (0.3%) correct and 1 par-
ticipant who scored 25/26 correct (0.3%).
Discussion
Our results showed that for analysis of ‘medication dose
needs adjustment’ awareness there were statistically sig-
nificant mean differences for total score of all medica-
tions, and also for allergy, endocrine, gastrointestinal
and rheumatologic medication classes among the PGY
groups with a consistent pattern of improved awareness
for PGY2 than PGY1 and also for PGY3 than PGY1.
Further, for endocrine medication class, there was
statistically significant improved awareness for PGY3 than
PGY2. There were no statistically significant mean differ-
ences among PGY groups for analgesic, cardiovascular and
neuropsychotropic medication classes. For the analysis of
the ‘medication dose adjustment at appropriate GFR level’
knowledge, there were statistically significant mean differ-
ences for total score of all medications, and also for allergy,
cardiovascular, endocrine and gastrointestinal medication
classes among the PGY groups with a consistent pattern of
improved knowledge for PGY2 than PGY1 and also for
PGY3 than PGY1. There were no statistically significant
mean differences among PGY groups for analgesic, neurop-
sychotropic, and rheumatologic medication classes.
Table 3 Comparisons for total scores of correct ‘medication dose adjustment at appropriate GFR level’ knowledge











Allergy 3 1.2 (0.81) 1.5 (0.71) 1.6 (0.57) <0.001 0.001 PGY2>PGY1
PGY3>PGY1
Analgesic 4 0.5 (0.69) 0.6 (0.77) 0.7 (0.66) 0.25 – –
Cardiovascular 7 2.1 (1.06) 2.4 (0.99) 2.5 (0.84) 0.004 0.03 PGY2>PGY1
PGY3>PGY1
Endocrine 3 0.7 (0.76) 0.9 (0.79) 1.1 (0.87) 0.001 0.001 PGY2>PGY1
PGY3>PGY1
Gastrointestinal 2 0.7 (0.55) 0.9 (0.50) 0.9 (0.45) 0.001 0.002 PGY2 > PGY1
PGY3>PGY1
Neuropsychotropic 5 1.4 (0.95) 1.6 (0.95) 1.5 (0.89) 0.34 – –
Rheumatologic 2 0.4 (0.62) 0.5 (0.73) 0.6 (0.76) 0.054 – –
Overall medication score 26 6.8 (3.09) 8.3 (2.91) 8.8 (2.02) <0.001 <0.001 PGY2>PGY1
PGY3>PGY1
Note: M mean, SD standard deviation, PGY post-graduate year, ANOVA analysis of variance, ANCOVA analysis of covariance. Sample sizes slightly vary due
to omissions by participants. Endocrine, pain, and rheumatologic had skewed distributions and non-parametric analyses of the Kruskall Wallis test were
performed instead of ANOVA. For endocrine, the Mann–Whitney test was performed instead of LSD post-hoc tests and rank ANCOVA (Quade’s test) was



























































Fig. 2 ‘Medication dose adjustment at appropriate GFR level’ knowledge. Percent ‘completely correct’ responses by PGY groups
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There was a consistent pattern of improvement in pre-
scribing for allergy, endocrine and gastrointestinal medi-
cation classes and also for the ‘overall medication score’
with increased level of training. At the statistically sig-
nificant level, both PGY2 and PGY3 demonstrated better
awareness for ‘medication dose needs adjustment’ and
better knowledge for ‘medication dose adjustment at ap-
propriate GFR level’ as compared to PGY1. There were
no statistical differences between PGY2 and PGY3 for
these medication classes except for endocrine medica-
tion class for the ‘medication dose needs adjustment’
awareness. For ‘overall medication score’, allergy and
gastrointestinal medication classes, our data trended to-
wards a better PGY3 score compared to PGY2, but this
was not statistically significant. Medical knowledge is ex-
pected to improve as residents advance through various
levels of training. The new Accreditation Council for
Graduate Medical Education (ACGME) accreditation
tool of ‘milestones’ is based on a similar principle that
focuses on continuous improvement in graduate medical
education, including the competency of medical know-
ledge [39]. As maintained by educational milestones, res-
idents are expected to demonstrate growth in their
medical knowledge at established intervals as they pro-
gress through training [39]. Our results are similar in
that increased level of training conferred greater know-
ledge from PGY1 to PGY2 and PGY3. However, even
with this greater knowledge for both PGY2 and PGY3,
there was still overall poor correct knowledge for these
medication classes.
There was no significant improvement in prescribing
pattern for analgesic and neuropsychotropic medication
classes for both ‘medication dose needs adjustment’
awareness and ‘medication dose adjustment at appropri-
ate GFR level’ knowledge. In addition, the overwhelming
majority had incorrect knowledge across all levels of
training. One possibility may be due to the limited ex-
posure and infrequent prescribing of these medications
by IM house-staff. Typically in academic settings, spe-
cialists (psychiatrists and neurologists) are involved with
prescribing and initiating these medications. Another
possibility is that some of these medications are con-
trolled substances and may not be routinely prescribed
by IM house-staff. This limited experience among IM
house-staff for some of these medications may contrib-
ute to the overall poor scores for these medication clas-
ses. Outside of academic settings, generalists prescribe
the majority (59 to 85%) of psychotropic medications in
the US [40, 41]. However, studies report suboptimal dos-
ing and duration with a lack of concordance between
psychiatric diagnoses and prescribed psychotropic medi-
cations among generalists [42–44]. This has resulted in
recommendations for graduate medical education pro-
grams to place greater emphasis on fundamental
prescribing practices for psychotropic drugs [45–48].
Despite these recommendations, our results demonstrate
poor knowledge about these medications among house-
staff. With generalists responsible for the majority of
these prescriptions, it is important that IM house-staff
are aware of and adhere to dosing guidelines.
There was no statistical significance between the PGY
levels for the ‘medication dose needs adjustment’ aware-
ness for cardiovascular medication class, although the
mean scores for PGY2 and PGY3 were greater than
PGY1. For ‘medication dose adjustment at appropriate
GFR level’ knowledge, PGY2 and PGY3 demonstrated
statistically significant greater knowledge as compared to
PGY1. Although PGY3 had a better score compared to
PGY2, this was not statistically significant. However,
even with this greater knowledge for PGY2 and PGY3 as
compared to PGY1, mean scores indicated incorrect
knowledge for more than half of the medications (i.e., at
least 4.5 of 7 medications not correct). These results are
surprising for the cardiovascular medication class. Car-
diovascular disease is the second most common cause of
hospitalizations in people over 65 years of age and is the
leading cause of morbidity and mortality in the US ac-
counting for almost 600,000 deaths in 2011 [49, 50]. IM
house-staff receive vast exposure to cardiovascular dis-
ease through various cardiology rotations (including car-
diac care unit, telemetry, cardiology consults, and
cardiology clinics) in addition to treating numerous pa-
tients on medical floors and continuity clinics during
residency. Furthermore, all IM house-staff are required
to comply with’Centers for Medicare and Medicaid Ser-
vices’ guidelines for inpatient (acute myocardial infarc-
tion and congestive heart failure) and outpatient (acute
myocardial infarction and chest pain) cardiovascular
core measures during all patient encounters [51]. One
possible reason for poor knowledge may be due to the
mild adverse effects associated with an extra dose of
most anti-hypertensive/cardiovascular medications. In a
study of young children with unintentional, single drug
exposure to commonly used antihypertensive medica-
tions (metoprolol, bisoprolol, ramipril, enalapril, lisino-
pril, captopril, candesartan, valsartan, amlodipine, and
verapamil), only mild symptoms occurred [52]. On the
contrary, certain medications like digoxin can cause ser-
ious adverse events with a single extra/higher dose in
patients with renal impairment. In our responses for di-
goxin, overwhelming majority (78.9%) of the house-staff
were more cognizant that this medication needs to be
adjusted in CKD.
There was a statistically significant mean difference
between various PGY levels for the ‘medication dose
needs adjustment’ awareness for rheumatologic medica-
tion class with PGY2 and PGY3 demonstrating better
awareness as compared to PGY1. There were no
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statistical significant differences between PGY2 and
PGY3, although PGY3 had higher mean scores. How-
ever, for the ‘medication dose adjustment at appropriate
GFR level’ knowledge, we only found increased know-
ledge approaching significance among the PGY groups
with mean scores improving as house-staff advanced
through training. Interestingly, rheumatologic medica-
tion class had the highest percentage of correct re-
sponses as compared to all other medication classes. It is
likely that the harmful side effect/adverse reaction pro-
file of these medications contributes to better awareness
and knowledge. A recent review of the safety and effi-
cacy of allopurinol in CKD suggests that incidence of
allopurinol hypersensitivity syndrome and other adverse
effects like Stevens-Johnson syndrome can occur with a
higher frequency in patients with impaired renal func-
tion [53]. Similarly, colchicine toxicity is more common
among those with renal impairment and can be fatal
[54–56].
Our sample data is fairly representative of the overall
IM house-staff across the US. In the 2012–2013 aca-
demic year, there were 23,597 IM house-staff across all
levels of training in the US [57]. The average age in our
study was 29.2 years with 46.3% female house-staff. This
is consistent with the US national average age of
29.4 years for IM house-staff with approximately 44% fe-
male house-staff [57]. The ACGME reports that there
were 43.9% of international medical graduates (IMGs) in
New York across all medical specialties as compared to
26.8% nationally [57]. Our sample had a similar percent-
age of IMGs as compared to the percentage of IMGs in
New York of 49%. Our distribution of house-staff based
on level of training is also consistent with the national
US statistics: 46.3 versus 43.0% for PGY1, 29.6 versus
29.0% for PGY2, and 24.0 versus 28.0% for PGY3 (our
sample versus US national average respectively) [57].
Our study has several limitations. First, the study was
limited to the metropolitan area of New York. Although
our sample was comparable in demographics to the total
IM house-staff across the US, there may be a difference
in patterns of training in different states. Second, the
number of medications in each class was different.
Third, the medications were selected based on our per-
ception of what was being commonly prescribed. Fourth,
we did not allow participants to use any automated sup-
port such as mobile- or computer-based devices for
guidance in adjusting prescription dose. Although in
clinical practice physicians have the opportunities to use
these tools, our study is relevant as in clinical practice
physicians are pressed for time and commonly do not
utilize these tools [58], particularly if they are not even
aware if a particular medication needs dose adjustment
in CKD. Therefore it’s important to have understanding
of resident physician awareness and knowledge.
Conclusions
House-staff across all levels of training demonstrated
poor awareness and knowledge of individualizing ther-
apy based on patient’s renal function. Poor knowledge of
renal dosing rules and lack of medication information
have been identified as major causes of prescribing er-
rors [59, 60]. Even with the use of electronic drug pre-
scribing systems, these systems do not often provide
guidance on the need for dose modification. It appears
that current medical training has deficiencies in the area
of renal dosing and thus potentially negatively impacts
patient safety. With the shortage of nephrologists and
the growing CKD population, it is essential that IM
house-staff receive more nephrology clinical exposure
and formal didactic educational training during resi-
dency to better manage the complex treatment regimens
and minimize morbidity due to medication dosing er-
rors. Future research should focus on approaches to im-
prove awareness and knowledge of medication use in
patients with CKD as adequate adjustment of the dosage
is an absolute requirement for appropriate and safe
prescribing.
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